← Back to Search

Behavioural Intervention

Automated Medication Dispensing for Dementia

Phase 2

Waitlist Available

Research Sponsored by HiDO Technologies

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Participants aged 65 or older

Be older than 65 years old

Must not have

Contraindications to taking low-dose Vitamin C (100 mg)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up measurements are collected at baseline, 6 months, and 12 months for both adherence and biomarker levels.

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to address the challenges in managing medication for older adults with dementia, particularly those with both Alzheimer's disease and type 2 diabetes. The trial will use a platform called HiDO-AL

Who is the study for?

This trial is for individuals with dementia, such as Alzheimer's Disease, who also may have type 2 diabetes. Participants should struggle with medication management and adherence. They must be able to use the HiDO-ALZ device which dispenses medications automatically using facial recognition and video monitoring.

What is being tested?

The HiDO-ALZ platform is being tested to see if it can help people with dementia manage their medications better by automating dispensing and providing caregivers access to adherence data through a cloud-connected dashboard.

What are the potential side effects?

Since this trial involves an automated medication dispensing system rather than a drug, there are no direct side effects like those associated with medications. However, technical issues or errors in dispensing could potentially occur.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 65 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I cannot take low-dose Vitamin C due to health reasons.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ measurements are collected at baseline, 6 months, and 12 months for both adherence and biomarker levels.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~measurements are collected at baseline, 6 months, and 12 months for both adherence and biomarker levels.

This trial's timeline: 3 weeks for screening, Varies for treatment, and measurements are collected at baseline, 6 months, and 12 months for both adherence and biomarker levels. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in Health Biomarker: Change in Creatinine Levels (mg/dL) Over 12 Months

Change in Health Biomarker: Change in Glomerular Filtration Rate (GFR) (mL/min/1.73 m²) Over 12 Months

Change in Health Biomarker: Change in Glucose Levels (mg/dL) Over 12 Months

+2 more

Secondary study objectives

Blood Pressure Monitoring (mmHg)

Monthly Heart Rate Tracking (beats per minute)

Monthly Weight Tracking

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: Usability StudyExperimental Treatment1 Intervention

This study, in collaboration with Rush Alzheimer's Disease Center, plans to recruit up to 20 participants aged 65 or older, along with their caregivers, to assess the usability and human factors of the HiDO-ALZ platform.

Group II: Field Efficacy Study - Experimental GroupExperimental Treatment1 Intervention

Participants in the experimental group will receive the HiDO-ALZ platform for 12 months, which provides automated medication dispensing, real-time facial recognition to ensure correct medication delivery, and biometric monitoring for blood pressure and weight. This arms plan to recruit up to 25 participants aged 65 or older, along with their caregivers, to assess the usability and human factors of the HiDO-ALZ platform.

Group III: Field Efficacy Study - Control GroupActive Control1 Intervention

Participants in the control group will receive standard care without the HiDO-ALZ device. They will continue with their usual medication routines and any standard biometric monitoring methods as directed by their healthcare providers. This arms plan to recruit up to 25 participants aged 65 or older, along with their caregivers, to assess the standard of care and not using the HiDO-ALZ device.

0 / 2Eligibility criteria met